The U.S. Food and Drug Administration has approved VEPPANU (vepdegestrant), marking a significant milestone as the first PROTAC (PROteolysis TArgeting Chimera) therapy to receive regulatory clearance for a solid tumour indication. Developed by Arvinas in collaboration with Pfizer, VEPPANU is indicated for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. The approval, which came ahead of the FDA-assigned PDUFA date of June 5, 2026, represents a paradigm shift in how targeted cancer therapies are designed. Unlike conventional inhibitors that block protein function, PROTAC molecules physically degrade the target protein — in this case, the oestrogen receptor — using the cell’s own ubiquitin-proteasome system. This degradation approach has shown the potential to overcome resistance mechanisms that frequently arise with standard endocrine therapies. ESR1 mutations are among the most common acquired resistance mechanisms in ER-positive breast cancer, emerging in 20–40% of patients who receive aromatase inhibitor therapy. VEPPANU was evaluated in the VERITAC-2 Phase 3 clinical trial, where it demonstrated superior progression-free survival compared to fulvestrant in patients with ESR1-mutated disease. “This approval validates the PROTAC platform as a clinically actionable modality and opens a new chapter in targeted oncology,” said an Arvinas spokesperson. The company and Pfizer expect to make VEPPANU available to patients in the United States in the coming weeks. The approval also underscores an intensifying focus on precision oncology tools capable of targeting previously “undruggable” proteins — …